ROCK inhibition prevents tau hyperphosphorylation and p25/CDK5 increase after global cerebral ischemia

Behav Neurosci. 2011 Jun;125(3):465-72. doi: 10.1037/a0023167.

Abstract

Rho-kinase (ROCK) is a downstream effector of RhoA, which has been associated with growth cone collapse and retraction in neurons. ROCK inhibition has been shown to protect against ischemic damage, thereby improving short-term collateral flow, inhibiting platelet aggregation, leukocyte adhesion, and preventing neuronal death. However, little is known about the long-term effects of ROCK inhibition on behavior and neuroprotection. The consequence of ROCK inhibition on ischemic rats' learning and spatial memory after 30 days of intracerebroventricular treatment was evaluated. It was found that Y27632 (ROCK inhibitor) reduced neurodegenerative markers, such as Fluoro-Jade, PHF (paired helicoidal filaments) immunoreactivity, and p25 protein levels, in the hippocampus of ischemic animals and improved learning and spatial memory tasks. However, Y27632 alone impaired sham animals' long-term memory. These findings demonstrated the beneficial impact of ROCK inhibition on tauopathy and altered p25 protein levels following global cerebral ischemia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / administration & dosage
  • Amides / pharmacology
  • Amides / therapeutic use
  • Animals
  • Brain Ischemia / drug therapy
  • Brain Ischemia / metabolism*
  • Brain Ischemia / psychology*
  • Cyclin-Dependent Kinase 5 / metabolism*
  • DNA-Binding Proteins / metabolism*
  • Disease Models, Animal
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Hippocampus / physiology
  • Injections, Intraventricular
  • Male
  • Maze Learning / drug effects
  • Maze Learning / physiology
  • Memory Disorders / chemically induced
  • Memory Disorders / drug therapy
  • Nerve Degeneration / drug therapy
  • Nerve Degeneration / metabolism
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Phosphorylation / drug effects
  • Pyridines / administration & dosage
  • Pyridines / pharmacology
  • Pyridines / therapeutic use
  • Rats
  • Rats, Wistar
  • Spatial Behavior / drug effects
  • Spatial Behavior / physiology
  • rho-Associated Kinases / antagonists & inhibitors*
  • rho-Associated Kinases / physiology
  • tau Proteins / metabolism*

Substances

  • Amides
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • Neuroprotective Agents
  • Pyridines
  • p25 protein (protein M subunit)
  • tau Proteins
  • Y 27632
  • Cyclin-Dependent Kinase 5
  • rho-Associated Kinases